MedTrace Logo

Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017

NCT04144842 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-04-24

No results posted yet for this study

Summary

The aim of the study is to assess the safety and tolerability of increasing doses of ATOR-1017 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.

Conditions

Interventions

BIOLOGICAL

ATOR-1017

ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)

Sponsors & Collaborators

  • Alligator Bioscience AB

    lead INDUSTRY

Principal Investigators

  • Sumeet Ambarkhane, MD · Alligator Bioscience AB

  • Gustav Ullenhag, Dr · Department of Oncology, Uppsala University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-03
Primary Completion
2023-03-29
Completion
2023-03-29

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04144842 on ClinicalTrials.gov